- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: GDC-0919 | NLG-919 | NLG919 | RG6078
Compound class: Synthetic organic
Comment: Navoximod (NLG-919) is a potent inhibitor of indoleamine-2,3-dioxygenase (IDO1) that was developed by Genentech and NewLink Genetics [2-3]. IOD1 is the first and rate-limiting component of the pathway mediating metabolism of tryptophan to kynurenine. Tryptophan depletion enhances the number and function of the Treg (suppressive) arm of the immune system and inhibits the effector T cell (stimulatory) arm. This action of IDO1 facilitates acquired local and peripheral immune tolerance in normal and pathological conditions. IOD1 inhibitors are being developed as novel therapeutics to reverse the immunosuppression associated with cancer.
The crystal structure of human IDO1 in complex with navoximod has been submitted to the PDB with ID 6O3I .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Navoximod has a favourable CYP450 profile, exhibits low hERG inhibition (71 μM) and has excellent solubility .|
|Selectivity at enzymes|
|Key to terms and symbols||Click column headers to sort|